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Left Ventricular Adaptation After TAVI Evaluated By Echocardiography
Including Speckle Tracking
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BACKGROUND Our study aimed to echocardiographically evaluate
myocardial adaption and outcome after transfemoral aortic valve
implantation (TAVI TF) for severe aortic stenosis based on LVEF.
METHODS From a total of 168 patients (pts.) who underwent TAVI TF
between 2010and2013 in our institution, n¼ 95with a follow-up-period3
months were included. Pts. were matched according to the Euro Score
(mean: 27.78 14.21%), anddivided into threegroups according tobaseline
left ventricular ejection fraction (LVEF; group 1: LVEF<40%,group2: LVEF
40%-55%, group3: LVEF>55%). LV functionwas assessedby conventional
and speckle-tracking based parameters. Mortality was registered up to 60
months (mean follow up period: 2917 months).
RESULTS Aortic valve oriﬁce and mean gradient signiﬁcantly
improved after TAVI in the whole collective in contrast to LV di-
mensions and LVEF, which largely remained unchanged (LV enddias-
tolic diameter: from 52.59.4 to 52.78.6mm; p¼0.59, LVEF from45.5
 10% to 47.8  13.9%, p¼0.13). However, pts. with reduced baseline
LVEF signiﬁcantly improved, while those with preserved LVEF
remained stable or slightly deteriorated (table 1). Changes of LVEF and
the global longitudinal strain (GLS) between group 1 and 3 were also
signiﬁcant (8.2  10.9% vs. -8.4  13.2%, p<0.0001 and -1.7  4.1% vs.
2.6  4.5%, p¼0.004 respectively). Kaplan Meier analysis revealed a
higher cumulative survival in patients with LVEF improvement as
compared to those with LVEF deterioration (p¼0.04, ﬁgure 1).Echocardiographic
parametersbaseline follow-upp-value
mean ± standard
deviation (median)mean ± standard
deviation (median)group1LVEF (Simpson, %) 29.98  8.31 (30) 39.47  12.28 (41) <0.001
GLS (%) -8.31  4.19 (-7.39) -9.01  3.69 (-3.94) 0.02
segmental strain
dispersion (msec)353.445  149.65
(353.50)315.49  118.13 (269) 0.04group 2LVEF (Simpson, %) 48.49  4.33 (49) 50.70  10.54 (48.22) 0.19
GLS (%) -12.12  4.50 (-12.02) -12.69  3.94 (-12.50) 0.28
segmental strain
dispersion (msec)271.85  120.10
(237.21)281.14  95.58 (275.19) 0.78group 3LVEF (Simpson, %) 65.19  7.02 (64) 56.59  13.17 (54.35) 0.004
GLS (%) -16.82  4.81 (-16.18) -14.59  5.12 (-14.08) 0.03
segmental strain
dispersion (msec)194.09  62.53
(185.01)230.70  123.99
(211.49)0.05CONCLUSIONS In patients with aortic stenosis and LVEF impairment
at baseline, TAVI results in an improved LVEF, while patients with a
high LVEF at baseline experience a normalization of LVEF after TAVI.
Independent of the baseline value, a deterioration of LVEF leads to a
signiﬁcant increase in mortality.
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BACKGROUND Transcatheter aortic valve implantation (TAVI) is a
treatment option for younger patients with symptomatic severe aortic
stenosis (AS) who seem to be high risk for surgical aortic valve
replacement due to signiﬁcant co-morbidities. However, very few
studies have investigated the feasibility and efﬁcacy of TAVI for
younger patients. Thus, the aim of this study is to evaluate the
feasibility and efﬁcacy of TAVI for younger patients.
METHODS Between October 2006 and October 2013, 790 consecutive
patients undergoing TAVI were included in the current analysis. The
cohort was divided into 2 groups: patients aged 75 years (n¼79) and
>75 years (n¼711).
RESULTS There were signiﬁcant differences with regard to major co-
morbidities which were more frequent in patients aged 75 years
compared to patients >75 years: history of cancer (22% vs 12%,
p<0.001), previous coronary artery bypass grafting (30% vs 11%,
p<0.001), and renal insufﬁciency requiring hemodialysis (11% vs 1%,
p¼0.007). With regard to echocardiography ﬁndings, ejection fraction
was signiﬁcantly lower in patients aged 75 years compared to pa-
tients >75 years (50.2% vs 54.4%, p¼0.016). With regard to outcomes,
there were no signiﬁcant differences in the procedural success rate
(92% vs 92%, p¼0.908), 30-day mortality (10% vs 11%, p¼0.747) and
30-day combined safety endpoint (21% vs 22%, p¼0.802) between the
2 groups. However, regarding mid-term outcome, the survival rate of
patients aged 75 years was signiﬁcantly higher in comparison with
patients aged >75 years (log-rank p¼0.037). The COX regression
model showed IDDM, life-threatening bleeding and creatinine clear-
ance (<60 ml/min) as the independent predictors of mid-term cu-
mulative mortality among younger patients.
CONCLUSIONS Although patients aged 75 years have more co-
morbidities compared to patients aged >75 years, TAVI can be effec-
tively and safely performed. Furthermore, mid-term outcome seems
to be better among the patients 75 years compared to patients aged
>75 years.
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BACKGROUND Based on data from the German Aortic Valve Registry
(GARY) a novel scoring system to predict 30-days or in hospital mor-
tality for either transvascular (tv) or transapical (ta) -TAVR was
developed.
METHODS 6249 pt undergoing tv-TAVR in 2011 and 2012 were
included in this ongoing non-randomized national multicenter regis-
try. In-hospital mortality or 30-days mortality (30dm) was chosen as a
binary outcome measure. First, 34 potential risk factors were tested in
an univariate manner by Fisher’s exact test for signiﬁcant inﬂuence on
mortality and multiple logistic regression with backward and forward
selection. Calibration was ascertained by the Hosmer-Lemeshow
